What it's for (Indications)
- Clomipramine, a tricyclic antidepressant (TCA), is primarily indicated for the treatment of Obsessive-Compulsive Disorder (OCD) in adults and pediatric patients 10 years of age and older.
- Its efficacy in alleviating the symptoms of OCD, including obsessions and compulsions, has been established through controlled clinical trials.
- While it has been historically used for various depressive disorders, its current primary FDA-approved indication specifically focuses on OCD.
- It may also be used off-label for certain other conditions such as panic disorder, chronic pain, and cataplexy associated with narcolepsy, but its on-label use is strictly for OCD where it has demonstrated significant therapeutic benefit by affecting serotonin neurotransmission.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of clomipramine must be carefully individualized and titrated to achieve optimal therapeutic effect while minimizing adverse reactions, particularly given its narrow therapeutic index. For adults with Obsessive-Compulsive Disorder (OCD), therapy typically begins with an initial dose of 25 mg orally once daily, usually at bedtime to mitigate sedation. The dosage is then gradually increased over the following weeks, generally in increments of 25-50 mg, to a target range of 100-150 mg per day, administered in divided doses or as a single dose at bedtime. The maximum recommended daily dose for adults is 250 mg. For pediatric patients (10-17 years of age) with OCD, treatment usually starts at 25 mg daily, escalating to a maximum of 3 mg/kg/day or 200 mg/day, whichever is less. Careful monitoring for side effects and therapeutic response is essential throughout the treatment period. |
Safety & Warnings
Common Side Effects
- Clomipramine, owing to its complex pharmacological profile, is associated with a wide range of potential side effects, many of which are characteristic of tricyclic antidepressants (TCAs).
- Common adverse reactions frequently reported by patients include pronounced anticholinergic effects such as dry mouth (xerostomia), blurred vision, constipation, and urinary retention.
- Central nervous system effects often manifest as sedation, dizziness, tremor, and headache.
- Cardiovascular side effects can include orthostatic hypotension, tachycardia, and ECG changes (e.
- g.
- , prolongation of QT interval, though less pronounced than some other TCAs).
- Other frequently observed effects involve weight gain, sexual dysfunction (e.
- g.
- , ejaculatory disturbances, impotence, decreased libido), nausea, sweating, and weakness.
- Less common but more serious adverse events include seizures (clomipramine can lower seizure threshold), hepatic dysfunction, agranulocytosis, and paradoxical psychiatric effects like mania or hypomania, especially in predisposed individuals.
- Patients should be counselled extensively regarding these potential effects.
Serious Warnings
- Black Box Warning: Antidepressants increase the risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to 24 years of age) in short-term studies. Patients of all ages starting antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Clomipramine is not approved for use in pediatric patients with major depressive disorder (MDD) but is approved for Obsessive-Compulsive Disorder (OCD) in pediatric patients 10 years of age and older. It is crucial to balance the clinical need with the potential risks. Prescribing should always consider the individual patient's risk-benefit profile, with particular attention to baseline suicidality risk and during dose adjustments.
- Beyond the black box warning concerning suicidality, clomipramine carries several other significant warnings that necessitate careful consideration during prescription and monitoring.
- Cardiovascular effects are a notable concern; clomipramine can cause orthostatic hypotension, tachycardia, and arrhythmias, posing risks particularly for patients with pre-existing cardiac conditions, and thus requiring baseline and periodic ECG monitoring.
- Its anticholinergic properties can exacerbate conditions like benign prostatic hypertrophy, angle-closure glaucoma, and paralytic ileus.
- Clomipramine may lower the seizure threshold, requiring extreme caution in patients with a history of seizure disorders, head trauma, or other conditions predisposing to seizures.
- Activation of mania or hypomania can occur in patients with bipolar disorder, necessitating careful screening prior to initiation.
- Abrupt discontinuation can lead to withdrawal symptoms such as nausea, vomiting, dizziness, headache, and irritability; therefore, dosage should be tapered gradually.
- Patients should be warned about impaired ability to perform hazardous tasks and the potentiating effect of alcohol and other CNS depressants.
- Hyponatremia has also been reported, especially in older adults, requiring electrolyte monitoring.
How it Works (Mechanism of Action)
Clomipramine primarily exerts its therapeutic effects by inhibiting the reuptake of neurotransmitters, particularly serotonin (5-HT) and to a lesser extent norepinephrine (NE), into presynaptic neurons in the central nervous system. This inhibition leads to an increased concentration of these neurotransmitters in the synaptic cleft, thereby enhancing serotonergic and noradrenergic transmission. Its potent and relatively selective serotonin reuptake inhibition is considered crucial for its efficacy in Obsessive-Compulsive Disorder (OCD). Beyond its reuptake inhibition properties, clomipramine and its active metabolite, desmethylclomipramine, also possess affinity for various other receptors. These include antagonism of muscarinic cholinergic receptors, alpha-1 adrenergic receptors, and histamine H1 receptors. These additional receptor interactions largely account for the prominent anticholinergic (e.g., dry mouth, constipation), sedative (H1 antagonism), and orthostatic hypotensive (alpha-1 antagonism) side effects commonly associated with clomipramine.
Commercial Brands (Alternatives)
No other brands found for this formula.